Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday. The brokerage presently has a $0.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 31.58% from the company’s current price.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Several other analysts have also recently weighed in on RTTR. Maxim Group reaffirmed a “hold” rating on shares of Ritter Pharmaceuticals in a research report on Friday, August 4th. Chardan Capital dropped their price target on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $4.88.

Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 0.57 on Friday. Ritter Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $3.75. The firm’s market capitalization is $8.41 million. The company’s 50-day moving average price is $0.57 and its 200-day moving average price is $1.05.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). Equities research analysts expect that Ritter Pharmaceuticals will post ($0.42) earnings per share for the current fiscal year.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/09/ritter-pharmaceuticals-inc-rttr-upgraded-to-buy-by-zacks-investment-research.html.

An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. lifted its stake in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,409 shares of the biotechnology company’s stock after purchasing an additional 76,046 shares during the quarter. KCG Holdings Inc. owned about 0.91% of Ritter Pharmaceuticals worth $150,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 7.62% of the company’s stock.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.